Valuation: Norda ASA

Market Cap 51Cr 5.53Cr 4.93Cr 4.52Cr 4.11Cr 7.72Cr 522.55Cr 7.9Cr 54Cr 22Cr 276.57Cr 21Cr 20Cr 876.13Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.85Cr 2.54Cr 2.33Cr 2.12Cr 3.98Cr 269.18Cr 4.07Cr 28Cr 11Cr 142.47Cr 11Cr 10Cr 451.32Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.06%
1 month+1.06%
3 months-0.46%
6 months+1.06%
Current year-14.00%
1 month 86
Extreme 86
86
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%-.--%+6.17%+109.76% 4.75Cr
+10.00%+5.18%+54.35%+71.20% 6.06TCr
+1.44%+5.05%+22.52%+99.64% 5.55TCr
+3.32%+2.31%+11.04%+76.48% 5.52TCr
+1.29%-4.49%+26.33%+34.33% 4.33TCr
+6.28%+1.12%+22.11%+92.50% 4.04TCr
+2.63%+5.37%+239.53%+823.21% 4.16TCr
-3.79%-7.50%+89.46%+78.72% 3.33TCr
+5.32%+6.04%+20.27%+52.98% 3.23TCr
+5.59%+12.90%-40.09%+359.27% 2.29TCr
Average +3.33%+4.62%+45.17%+179.81% 3.85TCr
Weighted average by Cap. +3.82%+4.06%+51.60%+171.71%

Financials

2023 2024
Net sales 8.69Cr 93.66L 83.46L 76.54L 69.55L 1.31Cr 89Cr 1.34Cr 9.15Cr 3.67Cr 47Cr 3.52Cr 3.44Cr 148.4Cr 37Cr 4.01Cr 3.57Cr 3.27Cr 2.98Cr 5.59Cr 378.65Cr 5.72Cr 39Cr 16Cr 200.41Cr 15Cr 15Cr 634.86Cr
Net income 3.12Cr 33.59L 29.93L 27.45L 24.94L 46.89L 32Cr 47.96L 3.28Cr 1.32Cr 17Cr 1.26Cr 1.23Cr 53Cr 13Cr 1.36Cr 1.21Cr 1.11Cr 1.01Cr 1.89Cr 128.25Cr 1.94Cr 13Cr 5.31Cr 68Cr 5.09Cr 4.98Cr 215.03Cr
Net Debt -31Cr -3.35Cr -2.99Cr -2.74Cr -2.49Cr -4.68Cr -316.93Cr -4.79Cr -33Cr -13Cr -167.74Cr -13Cr -12Cr -531.38Cr -25Cr -2.68Cr -2.39Cr -2.19Cr -1.99Cr -3.74Cr -253.36Cr -3.83Cr -26Cr -10Cr -134.1Cr -10Cr -9.85Cr -424.81Cr
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock